ArticleJournal of virology2026
A novel FcγRIIa-TRIM54-STAT2 axis negatively regulates type I interferon signaling and promotes viral susceptibility in human monocytes.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While adaptive humoral immunity and type I interferon (IFN-I) responses are known to cross-regulate each other during viral infection, the mechanisms by which antibodies (Abs) or immune complexes (ICs) modulate IFN-I signaling in immune cells remain unclear. Here, using plate-coated human IgG (cIgG) as an antigen-independent IC mimic, we show that FcγRIIa cross-linking in human blood monocytes induces the expression of TRIM54, an E3 ubiquitin ligase previously thought to be constitutively expressed only in muscle tissue. Mechanistically, TRIM54 binds to and promotes the ubiquitination of the transcriptional activator STAT2, thereby dampening the expression of many IFN-stimulated genes. This inhibitory role is functionally corroborated by a positive correlation between elevated TRIM54 levels and enhanced cellular permissiveness to infection by vesicular stomatitis virus, Dengue virus, and/or Sendai virus, in cIgG-primed human monocytes, and monocytic cell lines with genetically modulated TRIM54 expression. Clinically, elevated TRIM54 expression is detected in circulating monocytes from pediatric patients with Epstein-Barr virus-induced infectious mononucleosis. Together, our findings define a previously unrecognized FcγRIIa-TRIM54-STAT2 signaling axis through which virus-specific Abs-particularly at sub-neutralizing concentrations-can attenuate the IFN-I response in innate immune cells. This axis may also provide a mechanistic explanation for Ab-dependent enhancement of viral infection. IMPORTANCE: The long-standing question of how antigen-antibody immunocomplexes regulate type I interferon (IFN) signaling in immune cells remains unanswered. Our study uncovers a novel pathway for negative regulation of IFN-I signaling via the FcγRIIa-TRIM54-STAT2 axis in human monocytes. The novel concept will provide new insights into cross-regulation between humoral immunity and IFN response, and may provide important clues for the molecular mechanisms behind antibody-dependent enhancement of virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.